Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)


RevenueOwnershipFinancialsChart

Previous Close

$1.90

52W Range

$1.10 - $43.35

50D Avg

$5.37

200D Avg

$11.71

Market Cap

$2.55M

Avg Vol (3M)

$113.73K

Beta

1.84

Div Yield

-

EIGR Company Profile


Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

56

IPO Date

Jan 30, 2014

Website

EIGR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22
Product$12.73M
Other Revenue$750.00K

Fiscal year ends in Dec 23 | Currency in USD

EIGR Financial Summary


Dec 23Dec 22Dec 21
Revenue$15.77M$13.48M$12.14M
Operating Income$-71.79M$-92.74M$-76.94M
Net Income$-74.96M$-96.78M$-33.92M
EBITDA$-68.74M$-92.62M$-30.29M
Basic EPS$-50.78$-69.74$-29.98
Diluted EPS$-50.78$-69.74$-29.98

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 22Nov 03, 22 | 9:25 PM
Q2 22Aug 06, 22 | 8:23 PM
Q1 22May 08, 22 | 9:21 AM

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
NUVBNuvation Bio Inc.
XFORX4 Pharmaceuticals, Inc.
FUSNFusion Pharmaceuticals Inc.
APLTApplied Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
SPRBSpruce Biosciences, Inc.
SPROSpero Therapeutics, Inc.
FNCHFinch Therapeutics Group, Inc.
ETONEton Pharmaceuticals, Inc.
CINGCingulate Inc.
TERNTerns Pharmaceuticals, Inc.
CNTBConnect Biopharma Holdings Limited
BOLTBolt Biotherapeutics, Inc.
INZYInozyme Pharma, Inc.
ELDNEledon Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
HOWLWerewolf Therapeutics, Inc.
UNCYUnicycive Therapeutics, Inc.
NLTXNeurogene Inc.
CHRSCoherus BioSciences, Inc.
LYRALyra Therapeutics, Inc.